U.S. FDA Head Asks Congress For Import-Drug Inspection Funds
This article was originally published in PharmAsia News
Executive Summary
The head of the U.S. FDA broke with the administration to tell Congress his agency needs another $275 million if it is to inspect imported drugs and medical devices. Commissioner Andrew von Eschenbach wrote to a key senator to cite the need for offices in other countries and increased inspections. The funding request is beyond the administration's budget request submitted earlier this year. Since then, FDA has been under pressure to ensure the safety of drug imports in the wake of the tainted heparin scare in China. (Click here for more
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.